Filing Details
- Accession Number:
- 0001437749-23-017612
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-15 21:14:01
- Reporting Period:
- 2023-06-13
- Accepted Time:
- 2023-06-15 21:14:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1401667 | Puma Biotechnology Inc. | PBYI | Pharmaceutical Preparations (2834) | 770683487 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1589597 | Edward Troy Wilson | C/O Puma Biotechnolgy, Inc. 10880 Wilshire Boulevard, Suite 2150 Los Angeles CA 90024 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-06-13 | 27,000 | $3.45 | 350 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2023-06-13 | 27,000 | $0.00 | 27,350 | No | 4 | A | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | A | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 400 | Indirect | By Child #1 |
Common Stock | 150 | Indirect | By Child #2 |
Footnotes
- Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2022.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.43 to $3.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.